Streetbeat News

Regulatory

PHAT

Phathom Pharmaceuticals Inc (NASDAQ:PHAT) shares are trading higher after the company announced FDA approval of its reformulated vonoprazan tablets for both Voquenza Triple Pak and Voquenza Dual Pak for the treatment of Helicobacter pylori infection in adults. The company plans to host an investor call in November to discuss its U.S. commercial launch plans.

Portfolio Pulse from Adam Eckert

October 30, 2023 | 1:16 pm

ALPN

Alpine Immune Sciences, Inc. (NASDAQ:ALPN) announced it will present new translational data for povetacicept and acazicolcept in systemic lupus erythematosus at the American College of Rheumatology Convergence 2023. The data will be presented on November 14 and November 12, 2023, respectively. Both drugs are being developed for the treatment of autoimmune diseases, with povetacicept targeting BAFF and APRIL cytokines, and acazicolcept inhibiting the CD28 and ICOS T-cell costimulatory pathways.

Portfolio Pulse from Benzinga Newsdesk

October 30, 2023 | 1:15 pm

E

SLB

SLB's End-to-end Emissions Solutions business (SEES) has been selected by Eni to deliver comprehensive fugitive methane emissions measurement and reporting plans for Eni's global operating facilities. The project aligns with the United Nations' OGMP 2.0 reporting standards for methane emissions. The project aims to provide Eni with an accurate account of its fugitive methane emissions for transparent reporting purposes and to inform Eni's strategic efforts to reduce them.

Portfolio Pulse from Benzinga Newsdesk

October 30, 2023 | 1:14 pm

EWG

Germany's preliminary Consumer Price Index (CPI) for October came in at 0.0%, missing the estimated 0.2% and lower than the previous 0.3%.

Portfolio Pulse from Benzinga Newsdesk

October 30, 2023 | 1:11 pm

EWG

Germany's preliminary Consumer Price Index (CPI) for October is reported at 3.8%, lower than the estimated 4% and the previous 4.5%.

Portfolio Pulse from Benzinga Newsdesk

October 30, 2023 | 1:11 pm

INMB

INmune Bio, Inc. (NASDAQ:INMB) presented preclinical data at SITC 2023 showing that INB03, a dominant-negative inhibitor of soluble TNF, downregulates expression of SIRPα on macrophages to promote increased cancer cell death. The research examined animal models and human macrophages, showing that INB03 neutralizes sTNF, repolarizes tumor protecting M2 macrophages to M1 anti-tumor macrophages, enhances ADCP with trastuzumab, and reduces SIRPα expression. INB03 has completed an open label dose-escalation Phase I trial in patients with advanced cancer and was found to be safe and well tolerated.

Portfolio Pulse from Benzinga Newsdesk

October 30, 2023 | 1:08 pm

TSLA

Tesla, Inc. (NASDAQ:TSLA) has not seen a significant increase in volume despite price cuts since January this year. Tesla's VP of Investor Relations, Martin Viecha, expressed concern over the decline in the global EV market in H1 2023. However, Future Fund's Gary Black predicts a recovery in 2024 due to three factors: the $7,500 U.S. EV tax credit going off-invoice, the launch of the Cybertruck sparking interest in EVs, and the advancement of autonomous driving systems. Tesla's stock rose 1.30% to $210 in premarket trading on Monday.

Portfolio Pulse from Shanthi Rexaline

October 30, 2023 | 1:06 pm

SLS

Sellas Life Sciences has received Fast Track Designation from the FDA for SLS009, a treatment for relapsed/refractory Peripheral T-cell Lymphomas (PTCL). The drug demonstrated a 36.4% clinical response in a Phase 1 study, compared to the standard of care's 25.8% response rate. This designation accelerates SLS009's path to FDA submission for treatment of PTCL.

Portfolio Pulse from Benzinga Newsdesk

October 30, 2023 | 1:06 pm

DAWN

DCPH

VYNE

Deciphera Pharma (DCPH) shares are up after its study of patients with TGCT met primary and secondary endpoints. Day One Biopharmaceuticals (DAWN) shares rose after the FDA accepted its NDA for tovorafenib in relapsed or progressive pediatric low-grade glioma, granted priority review and assigned a PDUFA date of April 30, 2024. VYNE Therapeutics (VYNE) shares increased after announcing a private placement of $88 million and data from its Phase 1b trial evaluating once-daily dosing of VYN201 in patients with nonsegmental vitiligo.

Portfolio Pulse from ryanfaloona@benzinga.com

October 30, 2023 | 12:50 pm

BTCUSD

MARA

Marathon Digital Holdings Inc's shares are trading higher alongside the price of Bitcoin. The rise in Bitcoin's price is due to continued momentum sparked by spot ETF optimism, which is expected to increase demand and liquidity in the crypto space. BlackRock and other financial firms have made changes to their submissions for spot Bitcoin ETFs, and JPMorgan expects the SEC to approve a spot ETF within the next few months. Marathon Digital, a Bitcoin miner, is set to report its Q3 financial results on Nov. 8.

Portfolio Pulse from Adam Eckert

October 30, 2023 | 12:46 pm